PET Imaging With [18F]F-AraG in Advanced Non-small Cell Lung Cancer (NSCLC)
This is a prospective, single center, single-arm clinical trial in 20 patients with non-small cell lung cancer (NSCLC) undergoing PD-1/PD-L1-directed therapy. This research is being done to find out if the radioactive compound called \[18F\]F-AraG is a helpful imaging agent for detecting changes in cancer's anti-tumor immune response (or activation of T-cell) levels for non-small cell lung cancer (NSCLC) patients who will receive a cancer immunotherapy regimen (immunotherapy works by encouraging the body's own immune system to attack the cancer cells).
Checked against the public recordLast updated Jan 17, 2024 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Diagnostic
- Study type
- Interventional
- Phase
- Phase 1
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Interventions being studied
- Drug: [18F]F-AraG Injection
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Age 18 years or older and willing and able to provide informed consent. * Subjects with stage I, II, or III A NSCLC and plan to receive neoadjuvant PD-1/PD-L1 immunotherapy with an intention for curative surgery. Subjects will be receiving neoadjuvant immunotherapy through enrollment in therapeutic clinical trials * Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 at the time of enrollment. * For females of childbearing potential, negative serum pregnancy test within a 10 day period will be obtained prior to PET study. Exclusion Criteria: * Severe impaired renal function with estimated glomerular filtration rate \<30 mL/min/1.73 m2 and/or on dialysis. * Pregnant female patients; breastfeeding female patients. * Any medical condition that in the opinion of the study investigators would constitute a safety risk to the subject. * Any investigational radiation exposure in the past calendar year that in combination with the radiation exposure from this study would exceed 5 rem. * Administered a radioisotope ≤5 physical half-lives prior to the day of PET/CT.
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Johns Hopkins UniversityBaltimore, Maryland
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jan 17, 2024. Always confirm current availability with the study team.